MET and cholangiocarcinoma: Li et al. found that cyclin A2 (CCNA2) promoted the EMT progression combined with MET/AKT/GSK-3b via the ROCK/AKT/β-catenin pathway in bladder cancer 36, and aberrant activation of Wnt/β-catenin signaling was observed in the majority of CCA 37.